iBio, has established a strategic commercial relationship with specialist in plant molecular medicine technology research and product development, CC-Pharming, for the joint development of products and manufacturing facilities in China. Read more


Biosimilars are increasing in popularity with pharma companies, however, an important consideration for the interested parties is knowing which markets are saturated and which are still open, according to data and analytic company, GlobalData. Read more


Data from a randomised controlled trial, presented at the International Conference on Malignant Lymphoma (ICML) has shown Truxima (CT-P10) to be non-inferior to the reference product in terms of overall and complete response rates Read more